Treatment of male osteoporosis

Recent advances with alendronate

J. D. Ringe, Eric Orwoll, A. Daifotis, A. Lombardi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Overall, the data from the two alendronate studies clearly document the efficacy and safety of alendronate in osteoporotic men. The positive effects of alendronate on BMD, markers and fractures are very consistent between studies. Importantly, they are also very consistent with the results of multiple clinical studies conducted in postmenopausal women with osteoporosis. Treatment with 10 mg alendronate for 2 years produced significant and clinically meaningful increases in BMD, similar to those previously observed in postmenopausal women. Data from studies including men and women confirm the similarity of response suggested by singlegender studies. Consistent with much larger studies in postmenopausal women, alendronate 10 mg/day also reduced the incidence of new vertebral fracture and, correspondingly, reduced height loss. The safety and tolerability of alendronate in men was favorable and consistent with the safety profile previously observed in postmenopausal women. Alendronate represents an important and needed therapeutic advancement in the management of osteoporosis in men.

Original languageEnglish (US)
Pages (from-to)195-199
Number of pages5
JournalOsteoporosis International
Volume13
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Alendronate
Osteoporosis
Safety
Therapeutics
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of male osteoporosis : Recent advances with alendronate. / Ringe, J. D.; Orwoll, Eric; Daifotis, A.; Lombardi, A.

In: Osteoporosis International, Vol. 13, No. 3, 2002, p. 195-199.

Research output: Contribution to journalArticle

Ringe, J. D. ; Orwoll, Eric ; Daifotis, A. ; Lombardi, A. / Treatment of male osteoporosis : Recent advances with alendronate. In: Osteoporosis International. 2002 ; Vol. 13, No. 3. pp. 195-199.
@article{eb0049c198df465dbf8ceb937ddce1b8,
title = "Treatment of male osteoporosis: Recent advances with alendronate",
abstract = "Overall, the data from the two alendronate studies clearly document the efficacy and safety of alendronate in osteoporotic men. The positive effects of alendronate on BMD, markers and fractures are very consistent between studies. Importantly, they are also very consistent with the results of multiple clinical studies conducted in postmenopausal women with osteoporosis. Treatment with 10 mg alendronate for 2 years produced significant and clinically meaningful increases in BMD, similar to those previously observed in postmenopausal women. Data from studies including men and women confirm the similarity of response suggested by singlegender studies. Consistent with much larger studies in postmenopausal women, alendronate 10 mg/day also reduced the incidence of new vertebral fracture and, correspondingly, reduced height loss. The safety and tolerability of alendronate in men was favorable and consistent with the safety profile previously observed in postmenopausal women. Alendronate represents an important and needed therapeutic advancement in the management of osteoporosis in men.",
author = "Ringe, {J. D.} and Eric Orwoll and A. Daifotis and A. Lombardi",
year = "2002",
doi = "10.1007/s001980200013",
language = "English (US)",
volume = "13",
pages = "195--199",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "3",

}

TY - JOUR

T1 - Treatment of male osteoporosis

T2 - Recent advances with alendronate

AU - Ringe, J. D.

AU - Orwoll, Eric

AU - Daifotis, A.

AU - Lombardi, A.

PY - 2002

Y1 - 2002

N2 - Overall, the data from the two alendronate studies clearly document the efficacy and safety of alendronate in osteoporotic men. The positive effects of alendronate on BMD, markers and fractures are very consistent between studies. Importantly, they are also very consistent with the results of multiple clinical studies conducted in postmenopausal women with osteoporosis. Treatment with 10 mg alendronate for 2 years produced significant and clinically meaningful increases in BMD, similar to those previously observed in postmenopausal women. Data from studies including men and women confirm the similarity of response suggested by singlegender studies. Consistent with much larger studies in postmenopausal women, alendronate 10 mg/day also reduced the incidence of new vertebral fracture and, correspondingly, reduced height loss. The safety and tolerability of alendronate in men was favorable and consistent with the safety profile previously observed in postmenopausal women. Alendronate represents an important and needed therapeutic advancement in the management of osteoporosis in men.

AB - Overall, the data from the two alendronate studies clearly document the efficacy and safety of alendronate in osteoporotic men. The positive effects of alendronate on BMD, markers and fractures are very consistent between studies. Importantly, they are also very consistent with the results of multiple clinical studies conducted in postmenopausal women with osteoporosis. Treatment with 10 mg alendronate for 2 years produced significant and clinically meaningful increases in BMD, similar to those previously observed in postmenopausal women. Data from studies including men and women confirm the similarity of response suggested by singlegender studies. Consistent with much larger studies in postmenopausal women, alendronate 10 mg/day also reduced the incidence of new vertebral fracture and, correspondingly, reduced height loss. The safety and tolerability of alendronate in men was favorable and consistent with the safety profile previously observed in postmenopausal women. Alendronate represents an important and needed therapeutic advancement in the management of osteoporosis in men.

UR - http://www.scopus.com/inward/record.url?scp=0036117810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036117810&partnerID=8YFLogxK

U2 - 10.1007/s001980200013

DO - 10.1007/s001980200013

M3 - Article

VL - 13

SP - 195

EP - 199

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 3

ER -